339 related articles for article (PubMed ID: 37818370)
1. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.
Faiyazuddin M; Sophia A; Ashique S; Gholap AD; Gowri S; Mohanto S; Karthikeyan C; Nag S; Hussain A; Akhtar MS; Bakht MA; Ahmed MG; Rustagi S; Rodriguez-Morales AJ; Salas-Matta LA; Mohanty A; Bonilla-Aldana DK; Sah R
Front Immunol; 2023; 14():1264502. PubMed ID: 37818370
[TBL] [Abstract][Full Text] [Related]
2. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
3. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
4. An extensive review on antifungal approaches in the treatment of mucormycosis.
Chaudhari HS; Palkar OS; Abha Mishra KM; Sethi KK
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23417. PubMed ID: 37345721
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
7. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.
Hussain MK; Ahmed S; Khan A; Siddiqui AJ; Khatoon S; Jahan S
Eur J Med Chem; 2023 Jan; 246():115010. PubMed ID: 36566630
[TBL] [Abstract][Full Text] [Related]
8. Mucormycosis: The hidden and forgotten disease.
Darwish RM; AlMasri M; Al-Masri MM
J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271
[TBL] [Abstract][Full Text] [Related]
9. Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.
Taneja J; Chatterjee K; Sasidharan J; Abbas SZ; Rai AK; Raychaudhury S; Das B; Das A
Med Mycol; 2023 Jul; 61(7):. PubMed ID: 37442616
[TBL] [Abstract][Full Text] [Related]
10. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
11. Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.
Sharma N; Wani SN; Behl T; Singh S; Zahoor I; Sehgal A; Bhatia S; Al-Harrasi A; Aleya L; Bungau S
Environ Sci Pollut Res Int; 2023 Jan; 30(4):9164-9183. PubMed ID: 36454526
[TBL] [Abstract][Full Text] [Related]
12. Mucormycosis treatment: Recommendations, latest advances, and perspectives.
Brunet K; Rammaert B
J Mycol Med; 2020 Sep; 30(3):101007. PubMed ID: 32718789
[TBL] [Abstract][Full Text] [Related]
13. Why is mucormycosis more difficult to cure than more common mycoses?
Katragkou A; Walsh TJ; Roilides E
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():74-81. PubMed ID: 24279587
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy.
Ville S; Talarmin JP; Gaultier-Lintia A; Bouquié R; Sagan C; Le Pape P; Giral M; Morio F
Exp Clin Transplant; 2016 Feb; 14(1):96-9. PubMed ID: 25275881
[TBL] [Abstract][Full Text] [Related]
16. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
17. Mucormycosis threats: A systemic review.
Prakash S; Kumar A
J Basic Microbiol; 2023 Feb; 63(2):119-127. PubMed ID: 36333107
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
Abdorahimi M; Pakdel F; Salehi M; Alcazar-Fuoli L; Hashemi SJ; Daie Ghazvini R; Ahmadkhani F; Ahmadikia K; Abdollahi A; Debran JCS; Tabari A; Farrokh F; Mousavand A; Afarinesh Khaki P; Salami Khaneshan A; Ibrahim AS; Khodavaisy S
Mycopathologia; 2023 Oct; 188(5):783-792. PubMed ID: 37672164
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
[TBL] [Abstract][Full Text] [Related]
20. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
